



## Neuroprotective effects of PACAP against paraquat-induced oxidative stress in the *Drosophila* central nervous system

Khadija Hajji, Ali Mteyrek, Jun Sun, Marlène Cassar, Sana Mezghani, Jérôme Leprince, David Vaudry, Olfa Masmoudi-Kouki, Serge Birman

### ► To cite this version:

Khadija Hajji, Ali Mteyrek, Jun Sun, Marlène Cassar, Sana Mezghani, et al.. Neuroprotective effects of PACAP against paraquat-induced oxidative stress in the *Drosophila* central nervous system. *Human Molecular Genetics*, 2019, 28, pp.1905 - 1918. 10.1093/hmg/ddz031 . hal-02396061

**HAL Id: hal-02396061**

**<https://hal.science/hal-02396061>**

Submitted on 10 Dec 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Neuroprotective effects of PACAP against paraquat-induced  
oxidative stress in the *Drosophila* central nervous system**

Khadija Hajji<sup>1,2</sup>, Ali Mteyrek<sup>1</sup>, Jun Sun<sup>1</sup>, Marlène Cassar<sup>1</sup>, Sana Mezghani<sup>2</sup>, Jérôme  
Leprince<sup>3,4</sup>, David Vaudry<sup>3,4</sup>, Olfa Masmoudi-Kouki<sup>2,\*</sup> and Serge Birman<sup>1,\*</sup>

<sup>1</sup>Genes Circuits Rhythms and Neuropathology (GCRN) Group, Brain Plasticity Unit, CNRS,  
ESPCI Paris, Labex Memolife, PSL Research University, 10 rue Vauquelin, 75005 Paris, France

<sup>2</sup>University Tunis El Manar, Faculty of Sciences of Tunis, LR18ES03, Laboratory of  
Neurophysiology, Cellular Physiopathology and Biomolecules Valorisation, 2092 Tunis, Tunisie

<sup>3</sup>Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, INSERM  
U1239, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University,  
76821 Mont-Saint-Aignan, France

<sup>4</sup>Regional Cell Imaging Platform of Normandy (PRIMACEN), Normandy University,  
UNIROUEN, INSERM, 76821 Mont-Saint-Aignan, France

\*Address for correspondence and reprint requests to Serge Birman ([serge.birman@espci.fr](mailto:serge.birman@espci.fr)) and  
Olfa Masmoudi-Kouki, ([olfa.masmoudi@fst.utm.tn](mailto:olfa.masmoudi@fst.utm.tn))

## Abstract

Parkinson's disease (PD) is a progressive neurodegenerative movement disorder that can arise after long-term exposure to environmental oxidative stressors, such as the herbicide paraquat (PQ). Here we investigated the potential neuroprotective action of vertebrate pituitary adenylate cyclase-activating polypeptide (PACAP) against PQ in *Drosophila*. We found that pretreatment with this neuropeptide applied to the ventral nerve cord (VNC) at low doses markedly extended the survival of wild-type decapitated flies exposed to neurotoxic levels of PQ or dopamine (DA). In contrast and interestingly, application of a PACAP receptor antagonist, PACAP-6-38, had opposite effects, significantly decreasing the resistance of flies to PQ. PACAP also reduced PQ-induced caspase activation and reactive oxygen species (ROS) accumulation in the VNC. We then searched for the endogenous neuropeptide receptor potentially involved in PACAP-mediated neuroprotection in *Drosophila*. Knocking down the gene encoding the receptor Han/PDFR of the neuropeptide pigment-dispersing factor (PDF) in all neurons conferred to flies higher resistance to PQ, whereas PDFR downregulation restricted to PDF or DA neurons did not increase PQ resistance, but remarkably suppressed the neuroprotective action of PACAP. Further experiments performed with *Pdf* and *Pdfr*-deficient mutant strains confirmed that PDF and its receptor are required for PACAP-mediated neuroprotection in flies. We also provide evidence using split-GFP reconstitution that PDF neurons make synaptic contacts onto DA neurons in the abdominal VNC. Our results, therefore, suggest that the protective action of PACAP against PQ-induced defects in the *Drosophila* nervous system involves the modulation of PDFR signaling in a small number of interconnected neurons.

## Introduction

Parkinson's disease (PD) is a progressive neurodegenerative movement disorder believed to develop as a result of an interplay between genetic and environmental factors (1). The identification of genetic factors that modulate an individual's sensitivity to environmental agents can lead to better risk assessment and understanding of the disease mechanisms (2, 3). The motor symptoms of PD are primarily caused by the degeneration of dopaminergic (DA) neurons innervating the striatum whose cell bodies are located in the midbrain substantia nigra pars compacta (SNpc) (4). Epidemiological studies have suggested that long-term exposure to pesticides such as the herbicide paraquat (1,1'-dimethyl-4,4'-bipyridinium, PQ) is associated with an increased risk of developing PD (5–7). In accordance with this, PQ has been shown to induce the degeneration of nigrostriatal DA neurons in rodents (8–12), due to increased production of superoxide ions and oxidative damage (13–19).

The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP), originally identified as a highly potent adenylate cyclase-stimulating peptide with two biologically active isoforms, PACAP-38 and PACAP-27, exerts a wide range of actions *via* the activation of three G protein-coupled receptors (GPCRs): PAC1-R, which is PACAP-specific, and VPAC1-R and VPAC2-R indifferently activated by PACAP or vasoactive intestinal polypeptide (VIP) (20). PACAP is known as a powerful anti-apoptotic, anti-inflammatory and anti-oxidative agent (20–22). By reducing apoptosis, PACAP exhibits neuroprotective effects in diverse cellular and animal models of neuronal damage, including cerebral ischemia, brain injury, Alzheimer's disease and PD (23–27). In particular, it has been reported that PQ-induced loss of DA neurons was more severe in the SNpc of PACAP knock-out mice compared to wild-type animals, associated with increased microglial activation (25). This result indicates that endogenous



PACAP normally acts to maintain the integrity of SNpc DA neurons, an action that may be in part linked to its ability to regulate microglia and immune cells (25, 28).

One model system that has proven surprisingly tractable for neurodegenerative diseases is the fruit fly *Drosophila melanogaster*, which is now widely used to search for novel therapeutic targets and neuroprotective compounds (29–32). Previous reports have demonstrated that *Drosophila* exposed to environmental pro-oxidant toxins, such as rotenone or PQ, reproduce PD features, including selective degeneration of DA neurons (33–40). Neuropeptides are abundant in the *Drosophila* brain where they play essential roles in various physiological functions and behavior neuromodulation (41, 42). The fly *amnesiac* (*amn*) gene potentially encodes three neuropeptides, one of which displays a low (10%) identity to PACAP-38 and was previously considered as a possible PACAP orthologue (43–45), but there is still no direct evidence for the presence of *amn*-encoded neuropeptides in *Drosophila* (41). Nevertheless, a PACAP-like immunoreactivity was detected in the nervous system of various invertebrates (45, 46), and at the *Drosophila* larval neuromuscular junction (47). Focal application of vertebrate PACAP-38 to this glutamatergic synapse triggered two temporally distinct responses: an immediate depolarization and a large enhancement of potassium current (47). PACAP-38 also enhanced L-type calcium-current in larval muscles via the adenylate cyclase-cAMP-protein kinase A (PKA) transduction pathway (48). No specific receptor has been described to date that could mediate these effects. However, the receptor Han/PDFR of the neuropeptide pigment-dispersing factor (PDF), is homologous to the mammalian VIP/PACAP receptor VPAC2-R (49–51), and it has binding affinity for PACAP (51). Interestingly, both PACAP and PDF are “circadian neuropeptides” that play important roles in the regulation and entrainment of circadian rhythms in mammals and insects, respectively (42, 52, 53). Circadian clocks are highly conserved from flies to humans. They control rhythms in most physiological function, with free-running periods close to 24 h.

Clock disruption is suspected to reduce lifespan and quality of life during aging, and neurodegenerative disorders, like PD, often disrupt biological clocks early on (54, 55).

Here we assessed the protective effect of PACAP against PQ neurotoxicity in *Drosophila* and we searched for the G protein-coupled receptor (GPCR) mediating the action of PACAP in the central nervous system (CNS). We show evidence that the neuroprotective action of PACAP is conserved in *Drosophila* and specifically involves PDFR signaling in PDF and DA neurons.

## Results

### PACAP protects wild-type flies from PQ-induced neurotoxicity

To test the potential neuroprotective action of PACAP against PQ, administration via diet was not feasible because neuropeptides are vulnerable to intestinal peptidases. Therefore, we applied the neuropeptide onto the exposed ventral nerve cord (VNC) of decapitated flies, which can maintain a normal standing posture and survive up to 3 days when kept in a humid environment at 25°C (29, 39, 56, 57). We have previously shown in this preparation that a 5-s application of a drop of 80 mM PQ diluted in Ringer's solution onto the exposed VNC killed about 30-40% of the flies in 2 h (39).

Consistent with our previous report, PQ application decreased significantly the survival of decapitated flies and this effect was observed from the first 30 min after exposure (Fig. 1A). Remarkably, a 5-s application of a drop of 2  $\mu$ M PACAP (P) diluted in Ringer's solution, but not of Ringer's only (R), 30 min before that of PQ, markedly protected flies against PQ-induced lethality (Fig. 1A). The protective action of PACAP remained significant until 3 hours after PQ exposure. A maximal effect was observed at 120 min (+30.3%,  $p < 0.001$ ) for the survival of P + PQ vs R + PQ flies. Note that PACAP had no effect by itself on fly survival (P + R vs R + R, Fig.

1A). We have previously reported that DA itself can also be lethal when applied at 20 mM or higher to VNC in the same way as PQ (39). Here we observed that PACAP pretreatment fully rescued the flies from the lethality induced by the application of a drop of DA at 35 mM to the VNC (Supplementary Material, Fig. S1). These results show that PACAP is protective against both PQ- and DA-induced neurotoxicity in the *Drosophila* CNS.

The N-terminal residues of PACAP (PACAP-38 and PACAP-27) are essential for its biological activity. Consequently, the deleted peptide PACAP-6-38 is inactive and it is also a potent antagonist of the PACAP-specific receptor PAC1-R (58). We therefore investigated the effect of PACAP-6-38 on PQ sensitivity in *Drosophila*. Strikingly, we found that decapitated flies pre-treated for 30 min with 2  $\mu$ M PACAP-6-38 were significantly more susceptible to PQ than control flies (Supplementary Material, Fig. S2). In the presence of PACAP-6-38, fly survival was reduced by 20% and 19% ( $p < 0.001$ ) 60 and 90 min after PQ application, respectively. This shows that PACAP and PACAP6-38 applied to the VNC have opposite effects on oxidative stress resistance in *Drosophila*.

To learn more about the mechanisms of PACAP-mediated protection, we analyzed the effects of this neuropeptide on PQ-induced increase in reactive oxygen species (ROS) and caspase activation levels in the VNC. We estimated ROS levels by dihydroethidium (DHE) staining in wild-type Canton-S (CS) flies pre-treated or not with PACAP. We found that PACAP-treated flies exhibited significantly lower dye fluorescence in the VNC after 90 min of PQ exposure (–70%;  $p < 0.01$ ) (Fig. 1B and C). Similarly, using the CaspaseTracker biosensor system (59), which detects activation of the effector caspases, such as DrICE, that cleave protein substrates at a DQVD motif, we observed that PACAP pre-treatment significantly decreased the number of activated caspase-positive VNC cells in PQ-exposed decapitated flies (–40%;  $p < 0.01$ ) (Fig. 1D and E). Therefore, PACAP efficiently reduced the level of oxidative stress and caspase activation

under acute PQ intoxication in the *Drosophila* CNS.

### Neuronal downregulation of the PDF receptor decreases PQ susceptibility

In order to search for the neuropeptide receptor potentially involved in PACAP-mediated neuroprotection, genes encoding G protein-coupled receptors for several neuropeptides of the *Drosophila* CNS were downregulated by targeted RNA interference (RNAi) with the pan-neuronal driver *elav-Gal4* and co-expression of the RNAi booster *Dcr-2*, and adult fly survival was monitored 90 min after application of PQ (Table 1). Downregulation of *Dh31-R*, *Dh44-R1*, *Dh44-R2*, *FMRFaR*, and *sNPF-R* did not affect fly PQ susceptibility, or the protective effect of PACAP from PQ-provoked neurotoxicity. In contrast, silencing the gene *han/Pdfr*, which encodes the receptor for the neuropeptide pigment-dispersing factor (PDF), significantly increased *Drosophila* resistance to PQ, and PACAP pre-treatment did not further increase the survival rate of these flies (Table 1). We then analyzed the survival kinetics of flies in which *Pdfr* was either downregulated (Fig. 2A) or overexpressed (Fig. 2B) in all neurons, respectively. This confirmed that *Pdfr* silencing by RNAi significantly counteracted PQ-induced lethality from the first hour of exposure, while there was no detectable effect of PACAP in these conditions (Fig. 2A). In contrast, *Pdfr* overexpression in all neurons did not cause a noticeable effect on PQ susceptibility (Fig. 2B).

The receptor PDFR is widely expressed in the *Drosophila* clock neurons, and it is also expressed in non-clock brain cells as well as in peripheral clock cells (60, 61). Knocking down *Pdfr* by RNAi with the clock cell driver *tim-Gal4* (62, 63) conferred to decapitated flies a higher resistance to PQ, an effect that was highly significant between 90 and 150 min after PQ application (Fig. 2C). Such a protection (*tim>Pdfr*<sup>RNAi</sup>, *Dcr-2* flies, R + PQ) was comparable to that induced by PACAP pre-treatment on the controls (*Pdfr*<sup>RNAi/+</sup>, *Dcr-2/+*, P + PQ). Combining

the effects of PACAP pre-treatment and *Pdfr* knock down (i.e. *tim>Pdfr<sup>RNAi</sup>*, *Dcr-2*, P + PQ) did not further increase neuroprotection, indicating that these effects are apparently not additive (Fig. 2C). Note that a similar level of protection against PQ was observed when *Pdfr* RNAi was expressed with *elav-Gal4* or *tim-Gal4* in a parallel experiment (Fig. 2D). We also tested the effect of silencing the PDF receptor in glial cells using *repo-Gal4*, but the survival rate of these flies was not increased, suggesting that this cell type is not involved in the protective effect (Supplementary Material, Fig. S3).

It may seem surprising that knocking down *Pdfr* with the clock cell driver *tim-Gal4* had a protective effect on decapitated flies, because no clock neurons are present in the adult *Drosophila* VNC (63). However, it has been reported that *tim-GAL4* drives GFP expression in some neurons that do not express the TIM protein at detectable levels in the adult brain (63, 64). We have checked that this is also the case in the adult VNC. The pattern of membrane-associated GFP in the CNS of *tim>mCD8::GFP*, *nSyb::GFP* flies revealed that *tim-Gal4* expresses in several subsets of neurons in the abdominal ganglia (Supplementary Material, Fig. S4A). This region of the VNC also contains the abdominal (Abd) PDF neurons (65) and subsets of DA neurons (39). PDF co-immunostaining showed that *tim-Gal4* apparently does not label the Abd PDF neurons (Supplementary Material, Fig. S4B), in agreement with the observation that these cells do not express a molecular clock (65).

### Neuroprotection by PACAP requires PDF and the PDF receptor

We then tested the PQ resistance of a *Pdfr* null mutant strain, *Pdfr<sup>5304</sup>* (49). This strain appeared slightly more resistant than wild-type CS controls between 30 and 90 min after PQ application, but the effect was not statistically significant (Fig. 3A). Strikingly, we observed that PACAP pre-treatment did not induce protection against PQ in *Pdfr<sup>5304</sup>* mutant flies, suggesting

that PDF receptor signaling is required for the protective action of PACAP (Fig. 3A). To further assess this idea, we used the *Pdf<sup>01</sup>* null mutant line that does not express PDF (66). PACAP-mediated protection was indeed abolished in this strain (Fig. 3B). Therefore, PACAP requires both PDF and PDFR expression to promote neuroprotection.

We noted that the lack of PDF or PDFR did not increase PQ resistance (Fig. 3B), in contrast to the effect induced by RNAi-mediated *Pdfr* knock down in all neurons or clock cells, suggesting that *Pdfr* downregulation in neuronal subsets can induce different effects than its total absence. This result may suggest that it is a constitutive, and not PDF-stimulated, activity of PDFR that increases PQ susceptibility in wild-type flies. Alternatively, spontaneous mutations accumulated over generations (67) might have compensated for the lack of PDFR signaling for this specific phenotype in the *Pdfr<sup>5304</sup>* and *Pdfr<sup>01</sup>* mutants. To test these possibilities, we silenced PDF neuron activity by expressing the hyperpolarizing potassium channel Kir2.1 with the *Pdf-Gal4* driver (68). Interestingly, this led to significantly increased PQ resistance between 30 and 90 min of exposure (highest at 90 min: +27.7%,  $p < 0.001$ ) (Fig. 3C), indicating that PDF neuron activity is at least in part involved in PDFR-induced increase in PQ susceptibility. The rescue was not as strong as in the case of the *Pdfr<sup>RNAi</sup>* flies, which suggests that a constitutive activity of PDFR may indeed contribute to decrease oxidative stress resistance in wild-type flies. Furthermore, we observed that pre-treatment with 2  $\mu$ M (Fig. 3D), or even 20  $\mu$ M (Supplementary Material, Fig. S5), PDF had no effect on PQ resistance, suggesting that to increase PQ susceptibility in the CNS, not only PDF but also another signaling molecule is needed. This other molecule could be the unidentified classical neurotransmitter that is co-released with PDF by PDF neurons (69, 70).

### **The protective action of PACAP requires PDFR expression in PDF and DA neurons**

PDFR is known to be expressed in the PDF-producing neurons themselves, allowing an

211 autocrine modulation of these cells by the neuropeptide they release (60, 71). We observed that  
212 silencing PDFR selectively in PDF neurons with *Pdf-Gal4* (72) did not lead to increased PQ  
213 resistance, but fully prevented PACAP neuroprotective effects (Fig. 4A). Therefore, PDFR  
214 expression in the PDF neurons appears essential for PACAP-mediated neuroprotection. A quite  
215 similar effect was observed when we restricted PDFR knock down to the Abd PDF neurons of  
216 the VNC, using the *Dot-Gal4* driver (65). PQ susceptibility did not increase while the protective  
217 effect of PACAP was lost (Fig. 4B). This suggests that the presence of PDFR in the Abd PDF  
218 neurons is required for PACAP-mediated neuroprotection. We next investigated whether other  
219 neuronal cells could be involved in the protective effect of PACAP against PQ oxidative stress.  
220 Since DA neurons are very sensitive to PQ toxicity (39), we evaluated the effect of *Pdfr*  
221 downregulation in these cells using *TH-Gal4* (73). Interestingly, this also led to loss of PACAP  
222 protective effects, without increasing PQ resistance (Fig. 4C). PDFR appears therefore required  
223 both in PDF and DA neurons for PACAP-mediated neuroprotection.

224 These results prompted us to search for potential synaptic connections between the PDF and  
225 DA neurons in the *Drosophila* VNC by using split-GFP reconstitution (74). The fusion protein n-  
226 syb::spGFP1–10, which is targeted to synaptic vesicles (75), was expressed in PDF neurons with  
227 *Pdf-Gal4* and the other membrane-associated GFP moiety, CD4::spGFP11, in DA neurons using  
228 the *TH-LexA* driver, respectively (*PDF>nSyb::GFP<sub>1-10</sub>* + *TH>CD4::spGFP<sub>11</sub>* flies).  
229 Reconstituted split GFP (rsGFP) fluorescence was clearly visible in prominent bilateral axonal  
230 bundles located laterally in the abdominal ganglia (Fig. 5, arrowheads). In contrast, no specific  
231 rsGFP signal could be detected in the abdominal ganglia of *TH>nSyb::GFP<sub>1-10</sub>* +  
232 *PDF>CD4::spGFP<sub>11</sub>* flies (data not shown). These observations suggest that PDF neurons  
233 synapse onto DA neurons in this region of the VNC and not the reverse. Interestingly, these  
234 lateral axons appear to be also targeted by *tim-Gal4* (Fig. S4, arrows), suggesting that the

protective effect in the VNC of *tim>Pdf<sup>rRNAi</sup>* flies could specifically result from PDFR downregulation in these neurons. These lateral abdominal axons could be part of a neuronal network controlling oxidative stress susceptibility in *Drosophila*.

## Discussion

### The neuroprotective function of PACAP is conserved in *Drosophila*

The neuropeptide PACAP has been widely shown to have potent antioxidant and anti-apoptotic properties in several neuronal cell types *in vitro*, including cultured rat cerebellar granule neurons and astroglial cells, and *in vivo* models of ischemia, stroke, traumatic brain injury, multiple sclerosis, and of various neurodegenerative diseases such as Huntington's chorea, Alzheimer's disease and PD (21, 22, 76–80). Its neuroprotective action against DA neuron degeneration has been demonstrated in drug-induced PD models in rodents, using pro-oxidant toxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine (6-OHDA), rotenone and PQ (22, 81). PACAP injection also prolonged the survival of pond snails (*Lymnaea stagnalis*) exposed to rotenone, and partly rescued the reduction in locomotor activity and CNS DA level triggered by the toxin in this invertebrate model (82).

PACAP is also a survival-promoting peptide in mammalian species, playing major and pivotal roles in immunity and inflammation, and extending thereby the survival of mice with ileitis (intestinal inflammation) (83) and rats subjected to kidney ischemia-reperfusion (84). PACAP<sup>-/-</sup> null mutant mice show a high early-mortality rate, in part related to increased susceptibility to cold stress (85), and are poorly resistant to doxorubicin-induced myocardial damage (86). Moreover, PACAP<sup>-/-</sup> mice are more sensitive to PQ-induced DA neuron depletion, suggesting that endogenous PACAP has a physiological neuroprotective action in the brain (25).



Here we examined the effect of PACAP in a widely used sporadic PD model induced by PQ exposure in *Drosophila* (34, 37, 39, 87). Since the fly orthologue of PACAP has not yet been identified with confidence (41), we used the amino acid sequence of PACAP-38, which is identical in all mammals, and because PACAP could not cross the intestinal barrier and remain intact, we directly applied the neuropeptide to the exposed VNC of decapitated *Drosophila* before PQ exposure, using a previously established procedure (39). We repeatedly observed that PACAP pre-treatment at 2  $\mu$ M prolonged the survival of wild-type decapitated *Drosophila* exposed to PQ and that it was also protective against neurotoxic DA concentrations. In contrast, an opposite effect was observed, that is, an increase in fly susceptibility to PQ, when the antagonist PACAP-6-38 was applied, which is structural similar to PACAP-38 except for a short deletion of 5 amino acids in the N-terminal that suppresses its activity. This indicates that the neuroprotection conferred by PACAP in flies is a genuine and specific effect that requires the same structural domain than for its protective action in vertebrate systems. In addition, the opposite effect of the PACAP antagonist may suggest that a still unidentified, most likely peptidic, endogenous molecule, binds on the same receptor as PACAP and contributes to oxidative stress resistance in the *Drosophila* nervous system. We attempted to overexpress amnesiac in neurons (*elav>amn* flies), but this had no effect on PQ resistance (data not shown), suggesting that amn is not the functional counterpart of PACAP in the flies.

As was shown in mammalian cultured cerebral cells, PACAP is able: *i*) to stimulate endogenous antioxidant system by increasing the level of glutathione, the major free radical scavenger in the brain, and superoxide dismutase (SOD) and catalase activity, and *ii*) to prevent inhibition of endogenous ROS defense system under oxidative stress (77, 79, 80). This suggests that the neuropeptide could block ROS overproduction and dampen oxidative stress through an upregulation of ROS-detoxifying enzymes *in vivo*. Consistent with this observation, it has been

shown that enhancing antioxidant SOD2 and glutathione peroxidase 1 (GPX1) activity by PACAP provided protection against oxidative damage and neuroprotection in mice with traumatic brain injury (88) and that inhibition of the endogenous antioxidant system in astrocytes suppresses the cell survival-promoting effect of PACAP under oxidative conditions (80). Here we show accordingly that PACAP efficiently alleviated the increase in ROS accumulation triggered by PQ in the fly VNC. A possible effect of PACAP on the activity of endogenous antioxidant systems in PQ-treated *Drosophila* could thus be a key player in its mechanisms of action. These results are striking because PQ is a very strong inducer of ROS production in *Drosophila* (18, 39, 40, 87, 89), and we found here that a low dose of PACAP was sufficient to largely prevent the neurotoxic effects of this herbicide.

Previous work demonstrated that PACAP prevents cerebellar granule neurons from apoptotic cell death through inhibition of caspase-3 activity (90). Comparably, in the mollusk *Helix pomatia*, PACAP efficiently attenuated caspase-3 activation induced by cytotoxic levels of DA (91). We have thus investigated the effect of PACAP on PQ-induced activation of effector caspases in the *Drosophila* CNS with the CaspaseTracker biosensor system (59). PQ is known to cause an increase in caspase activity, both in mice and *Drosophila* (40, 92, 93). Pre-treatment of the flies with the neuropeptide PACAP significantly decreased caspase activation under PQ in the VNC, possibly resulting from oxidative stress reduction. It has been reported indeed that PACAP can regulate the expression of Bcl-2 family members to prevent apoptotic cell death provoked by oxidative insult in neuronal cells (21, 93, 94).

### **PDFR signaling significantly contributes to PQ neurotoxicity in the *Drosophila* CNS**

How can such a tiny amount of PACAP (40,000 times less than PQ) prevent oxidative stress-induced defects in the whole VNC and thus significantly prolong the survival of PQ-intoxicated

decapitated *Drosophila*? To explore the mechanisms of action of this neuropeptide, we first used pan-neuronal RNAi downregulation to search among GPCR receptors of known fly neuropeptides for one that might be implicated in the protective effect of PACAP. Among the six GPCRs that were tested, only PDFR was identified as being involved in the modulation of PQ sensitivity and PACAP-mediated neuroprotection. Indeed, downregulating this receptor in all neurons with *elav-Gal4*, or in *tim-Gal4*-targeted cells, was sufficient to protect efficiently the flies from PQ-induced early lethality. This indicates that PDFR signaling, which acts through elevated cAMP/PKA activity (51, 69, 71, 95–99) and modulation of  $\text{Ca}^{2+}$  level and activities (51, 96, 98, 100, 101), potently contributes to PQ susceptibility in *Drosophila*. In contrast, *Pdfr*<sup>5304</sup> and *Pdfr*<sup>0</sup> null mutants did not appear more resistant to PQ than wild-type flies, which might be related to compensating spontaneous mutations accumulated in the mutant genomes over generations (67), or, alternatively, to the absence of PDFR signaling at all stages and in all cells in the mutants compared to a relative downregulation in neurons only in the RNAi experiment. Note that *Pdfr* knock down by RNAi in PDF neurons was not sufficient to decrease PQ susceptibility, indicating that enhanced PQ resistance requires targeting other *Pdfr*-expressing neurons.

The fact that PDF release is involved in PDFR-induced increase in PQ susceptibility was suggested by the Kir2.1 experiment, in which *in vivo* silencing of PDF neurons with this potassium channel significantly enhanced PQ resistance of the flies. However, we show here that direct PDF application to the VNC of decapitated flies had no effect on PQ susceptibility, and we also observed that pan-neuronal expression of membrane-tethered PDF (t-PDF) (99) similarly did not affect PQ sensitivity of the flies (data not shown). This suggests that an additional molecule is required, potentially the classical transmitter that is co-released with PDF by PDF neurons (69). Indeed, these last authors showed the release of this co-transmitter is also increased by PDFR

329 auto-receptor activation.

330 By which mechanisms could PDFR signaling contribute prominently to PQ neurotoxicity is a  
331 matter of speculation. It has been demonstrated that PDF can convey signals that lead to  
332 activation of caspases and enhanced neurodegeneration in target cells in several parts of the  
333 *Drosophila* brain (102). This occurred in young flies with circadian dysfunction and in older  
334 wild-type flies. These effects correlated with enhanced tauopathy in a fly model of Alzheimer's  
335 disease (102). We have also recently reported that a mutation in the circadian gene *Clock* (*Clk<sup>AR</sup>*),  
336 or RNAi-induced *Clk* knock down in PDF neurons, led to accelerated age-related locomotor  
337 decline and apoptosis-related loss of DA neurons in the PPL1 cluster, all effects which were  
338 found to be strictly dependent on PDFR signaling (103). These and other findings suggest the  
339 implication of the circadian system and PDF/PDFR signaling in age-related loss of physical or  
340 cognitive abilities and enhanced neurodegeneration in *Drosophila* (104–106).

341 The ROS-related disturbance induced by PQ exposure could trigger the depolarization of PDF  
342 neurons, thus promoting caspase activation and apoptosis in *Pdfr*-expressing target cells, and the  
343 increased resistance to PQ when *Pdfr* is downregulated in *tim*-expressing neurons might be the  
344 result of the negative regulation of these molecular events. PDF neuron overactivation could  
345 directly or indirectly lead to similar defects in DA neurons, which would result in abnormally  
346 high level of DA release, inducing cytotoxic and excitotoxic effects through overstimulation of  
347 the D<sub>1/5</sub>-like DA receptor DAMB, which, as we have previously reported, can provoke calcium  
348 release in the cytosol of glutamatergic neurons through the ryanodine receptor and finally  
349 contribute to nervous system failure in PQ-intoxicated flies (39).

#### 350 **PACAP neuroprotection depends on PDFR signaling in PDF and DA neurons**

351 We observed that PACAP pre-treatment did not prolong the survival of PQ-exposed null *Pdfr*<sup>01</sup>

or *Pdfr*<sup>5304</sup> mutants that are deficient for PDF and PDFR, respectively, at variance with the potent protective effect of this neuropeptide on wild-type flies. No effect of PACAP could be detected after *Pdfr* downregulation in all neurons or in all clock cells, but this could be because PQ resistance was already much increased in these flies. In contrast, targeting *Pdfr* RNAi in PDF neurons selectively did not increase PQ resistance and instead fully prevented PACAP protective effects. Furthermore, restricting *Pdfr* RNAi knock down in the VNC Abd PDF neurons also suppressed the beneficial effect of PACAP pre-treatment for fly survival under acute oxidative stress. Although PDFR has binding affinity for PACAP *in vitro* (51), PACAP is apparently not an agonist of this receptor since it has been shown that its application to dissected brain did not significantly alter the FRET signal of a cAMP sensor in the PDF neurons that express PDFR (71).

In adult *Drosophila*, there are only ~24 PDF-expressing neurons in the CNS: four or five large (l-LN<sub>v</sub>s) and four small (s-LN<sub>v</sub>s) ventral lateral neurons per hemisphere in the brain, and four large (l-Abd) and four small (s-Abd) abdominal neurons in the VNC (98, 107, 108). It is known that brain PDF neurons (the s-LN<sub>v</sub>s and some of the l-LN<sub>v</sub>s) express PDFR autoreceptors (60, 69). The l-Abd and s-Abd PDF neurons do not express the molecular clock and the PDF neuropeptides released from these neurons are not required for locomotor rhythms (65). Nevertheless, both the brain LN<sub>v</sub>s and VNC Abd PDF neurons contribute to the normal phasing of the molecular clock in the oenocytes, which are pheromone-producing peripheral clock cells (61, 98). Furthermore, only the PDF released from the Abd PDF neurons is necessary to maintain wild-type expression levels of male sex pheromones (61).

Since we have performed our experiments on decapitated flies, it is natural to consider that the PDF neurons in which PDFR is required for PACAP neuroprotection are specifically the Abd neurons. This seems to be supported indeed by the fact that *Dot>Pdfr*<sup>RNAi</sup> decapitated flies are not

sensitive to PACAP. However, we cannot exclude that long-term PDFR deficiency in the brain PDF neurons might have a distant influence on other organs, including the VNC, that would contribute to PACAP-induced protection. Such an influence would have to be indirect because it is known that the brain PDF neurons do not send descending projections to the VNC (108). It is quite possible that, like for the phasing of oenocyte molecular clock, full PACAP neuroprotection requires PDFR expression in both the brain and VNC PDF neurons. Note that the same issue arises for the higher PQ resistance of decapitated flies in which *Pdfr* was downregulated with *tim-Gal4*. It is possible that the higher PQ resistance of *tim>Pdfr<sup>RNAi</sup>* flies results from long-term PDFR deficiency in the brain clock neurons that would make decapitated flies less susceptible to PQ neurotoxicity by a systemic mechanism. However, we show here that *tim-Gal4* expresses in subsets of neurons in the abdominal ganglia, some of which could express PDFR (the PDFR pattern has not been described in the VNC to date) and be directly involved in the control of PQ susceptibility in the CNS.

Finally, we observed that downregulating *Pdfr* in DA neurons also prevented PACAP-mediated neuroprotection. As in the case of PDF neurons, both the brain and VNC DA neurons could be involved in this effect, even though we used decapitated flies for the survival test. A recent report provided evidence that a subset of dopaminergic neurons respond to PDF and that the s-LN<sub>v</sub> axons and some brain DA neurons form synaptic contacts in the brain (109). As mentioned above, we have also previously shown that *Clk* downregulation in the sLN<sub>v</sub>s leads to PDFR-dependent degeneration of DA neurons (103). Here we show using split-GFP reconstitution that Abd PDF neurons also contact DA neurons in the abdominal region of the VNC, before these PDF neurons send projections out of the VNC (98). The synapses appear distributed along large bilateral axonal bundles. The fact that the silencing of PDFR in either PDF or DA neurons has no effect on the sensitivity of the flies to PQ, may suggest that PDFR has to

be knocked down in both cell types and probably in other clock neurons to increase PQ resistance. Remarkably, downregulating PDFR either in PDF or DA neurons was sufficient to fully prevent PACAP neuroprotection, indicating that PACAP must act on these two neuronal subsets to protect flies from PQ.

In conclusion, our current findings indicate that the neuropeptide PACAP offers a potent protection against PQ neurotoxicity in *Drosophila* and that this effect can be ascribed to the modulation of PDF/PDFR signaling in specific neuronal subsets. Further studies are required to characterize the signaling pathways that trigger this neuroprotective effect and so better understand the neuronal circuits and mechanisms controlling oxidative stress susceptibility in the *Drosophila* CNS.

## Materials and methods

### *Drosophila* culture and strains

Fly stocks were raised at 25°C on standard cornmeal-yeast-agar medium supplemented with methyl-4-hydroxy-benzoate as a mold protector, under 12 h-12 h light-dark cycle and 70% humidity. The following strains were used: Canton-S (CS) as wild type, *Pdfr*<sup>5304</sup> (49), *Pdfr*<sup>01</sup> (66), *elav-GAL4* (110), *repo-GAL4* (111), *TH-Gal4* (73), *TH-LexA* (112) (kindly provided by Dr. Ronald L. Davis), *tim-Gal4* (62), *Pdf-Gal4* (72), *Dot-Gal4* (65), *UAS-Pdfr* (49) (kindly provided by Dr. François Rouyer), *UAS-Kir2.1* (113) (kindly provided by Dr. Sean Sweeney), recombined *UAS-mCD8::GFP*, *UAS-nSyb::GFP* (114), and from the Bloomington *Drosophila* Stock Center (BDSC): *elav-Gal4*; *UAS-Dcr-2* (BDSC #25750); *UAS-Dcr-2*; *Pin*<sup>1</sup>/*CyO* (BDSC #24644), *LexAop-n-syb::spGFP<sub>1-10</sub>*, *UAS-CD4::spGFP<sub>11</sub>* (BDSC #64314); *UAS-n-syb::spGFP<sub>1-10</sub>*, *LexAop-CD4::spGFP<sub>11</sub>* (BDSC #64315), and the TRiP RNAi strains: JF01945 (BDSC #25925), JF03208

(BDSC #28780), JF03289 (BDSC #29610), JF02657 (BDSC #27507), HMJ02073 (BDSC #42508) and JF01879 (BDSC #25858), to knock down *Dh31-R*, *Dh44-R1*, *Dh44-R2*, *sNPF-R*, *Pdfr* and *FMRFaR*, respectively.

#### **PQ and PACAP application and survival score**

PQ and PACAP treatments were performed on 9 to 11-day-old adult females by direct application of the drug and neuropeptide onto the exposed VNC of decapitated flies as previously described (39). Briefly, flies were anaesthetized on ice for 10 min and their heads were cut off with 7-mm blade spring scissors (Fine Science tools). ~30 decapitated flies per condition were transferred to a 2-inch Petri dish (10 flies per dish) and allowed to recover for a few minutes until they stood on their legs. A 5 µl droplet of PQ (methyl viologen dichloride hydrate; Sigma-Aldrich 856177) diluted in *Drosophila* Ringer's solution (in mM: 130 NaCl, 4.7 KCl, 1.8 CaCl<sub>2</sub>, 0.5 Na<sub>2</sub>HPO<sub>4</sub>, 0.35 KH<sub>2</sub>PO<sub>4</sub>, pH 7.4 adjusted with 150 Na<sub>2</sub>HPO<sub>4</sub>) or Ringer's only (R) for controls, was applied for 5 s with a P10 Pipetman. The same droplet was successively used for 10 flies. A concentration of 80 mM PQ was generally used that gave 30-40 % survival of wild type flies after 2 h (39). Flies were considered as dead when they laid on the side or back and did not react to a slight mechanical stimulus on the legs. Survival rate was monitored every 30 min. Each experiment was repeated independently at least twice. The same procedure was used for DA application to the VNC except that DA concentration in the droplet was 35 mM, as previously described (39). For PACAP, PACAP-6-38 and PDF pretreatments, a droplet containing the neuropeptide at 2 µM (precisely 2.2 µM, i.e. 10, 8.9 and 4.3 µg/ml, respectively), in Ringer's, or 20 µM for PDF in some experiments, was applied to the decapitated flies the same way 30 min prior to the exposure to PQ. The 38-amino acid form of PACAP (His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-



Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH<sub>2</sub>) was synthesized by solid-phase methodology as previously described (115). PACAP-6-38 was purchased from Tocris Bioscience, Bristol, UK, and *Drosophila* PDF (Asn-Ser-Glu-Leu-Ile-Asn-Ser-Leu-Leu-Ser-Leu-Pro-Lys-Asn-Met-Asn-Asp-Ala-NH<sub>2</sub>) from NovoPro Bioscience Inc., Shanghai, China.

#### **Detection of caspase activity**

We have used the CaspaseTracker biosensor system to detect caspase activity in VNC cells of adult flies exposed to PQ. This system is composed of two genetic components: a biosensor encoding the Gal4 transcription factor sequestered in the cytoplasm by a caspase-cleavable membrane anchor (59), and the G-TRACE fluorescent protein system (116). Following caspase activation, Gal4 is released from its membrane anchor, translocates to the nucleus and drives the expression of both cytosolic red fluorescent protein (RFP), indicating recent or on-going caspase activity, and FLP recombinase, which induces permanent expression of nucleus-targeted GFP. 10-11-day-old CaspaseTracker female flies were pretreated with either Ringer's alone (controls) or 10 µg/ml PACAP in the same solution for 30 min before applying PQ. After 90 min of PQ treatment, 4 or 5 VNCs per condition were dissected in Ca<sup>2+</sup>-free Ringer's, fixed in 4% (wt/vol) paraformaldehyde in phosphate-buffered saline (PBS: 130 mM NaCl, 7 mM Na<sub>2</sub>HPO<sub>4</sub>, 3 mM KH<sub>2</sub>PO<sub>4</sub>), washed 3 times in PBS and then mounted for confocal microscopy examination.

#### **ROS measurement**

ROS detection in the *Drosophila* CNS was performed using the dihydroethidium (DHE) dye (Life technologies) following a previously described procedure (117, 118). 10-day-old decapitated female flies were exposed to PQ for 90 min with or without (control) 30-min pretreatment with PACAP. Their VNCs were dissected in Schneider's Insect Medium, and incubated in 30 µM DHE in the same medium for 5 min in the dark. After 5 min of fixation in

7% formaldehyde in PBS (pH 7, at room temperature), the VNCs were immediately imaged on a confocal microscope, as indicated below. Relative ROS levels were measured by quantification of the average intensity of the dye fluorescence using the Fiji software (119).

### **Immunohistochemistry and split-GFP reconstitution**

Whole-mount VNC immunostaining was performed as previously described (39, 120). The primary antibodies were mouse monoclonal anti-GFP (Sigma-Aldrich G6539, 1:200 or 1:250), rabbit polyclonal anti-PDF (kindly provided by Dr. François Rouyer, 1:100) and rabbit polyclonal anti-TH (Novus Biologicals NB300-109, 1:1000). The secondary antibodies were goat anti-mouse and anti-rabbit conjugated to Alexa Fluor 488 or 555 (Invitrogen Molecular Probes, 1:250 or 1:1000). For the visualization of potential synaptic connectivity by split-GFP reconstitution (GRASP method) (74, 75), the *Drosophila* lines *LexAop-n-syb::spGFP<sub>1-10</sub>*, *UAS-CD4::spGFP<sub>11</sub>* and *UAS-n-syb::spGFP<sub>1-10</sub>*, *LexAop-CD4::spGFP<sub>11</sub>* were crossed to the recombined driver line *Pdf-Gal4; TH-LexA*. The VNCs of 7-10-day-old female flies were dissected and processed for TH and GFP co-immunostaining.

### **Fluorescence confocal microscopy**

VNCs were mounted on slides using as antifade reagent, either ProLong Gold Antifade reagent (ThermoFisher Scientific) for CaspaseTracker staining, or Vectashield (Vector Laboratories) for ROS measurements. Images were acquired with a Nikon A1R confocal microscope. A minimum of 4 or 5 VNCs were scored over at least 3 trials. Laser, filter and gain settings remained constant within each experiment, and channels were scanned sequentially. Confocal Z-stacks were analyzed and processed using the Fiji software.

### **Statistical analysis**

Statistical analyses were performed with Prism 6 (GraphPad Software, La Jolla, CA, USA), using either one-way or two-way ANOVA with Tukey's *post-hoc* multiple comparison test, or Student's *t* test. Errors bars represent standard errors of the mean (SEM) of 3 or 4 independent determinations. Statistical significance in all figures: \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

## Acknowledgments

We thank Drs Ronald L. Davis, Paul Taghert, François Rouyer and Sean Sweeney for providing *Drosophila* stocks, Dr. François Rouyer for the gift of anti-PDF antibody and Dr. Paul Taghert for helpful suggestions. This work was supported by a France-Tunisia CMCU-Campus France/PHC Utique 16G0820 /34940PK exchange program to Olfa Masmoudi-Kouki and David Vaudry, and funding from Fondation de France, PSL Research University, ESPCI Paris and Labex MemoLife (ANR-10-LABX-54 MEMO LIFE) to SB. Funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Khadija Hajji's PhD was supported by fellowships from the Tunisian Higher Education Ministry, Tunis University LR18ES03, France-Tunisia exchange program PHC-Utique and the French Société de Neuroendocrinologie.

## Conflict of interest statement

The authors have no conflict of interest to declare.

## References

1. Kalia, L.V. and Lang, A.E. (2015) Parkinson's disease. *Lancet*, **386**, 896–912.
2. Ritz, B., Rhodes, S.L., Bordelon, Y. and Bronstein, J. (2012)  $\alpha$ -Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. *PLoS. ONE*, **7**, e36199.
3. Fleming, S.M. (2017) Mechanisms of gene-environment interactions in Parkinson's disease. *Curr. Environ. Health. Rep.*, **4**, 192–199.
4. Forno, L.S. (1996) Neuropathology of Parkinson's disease. *J. Neuropathol. Exp. Neurol.*, **55**, 259–272.
5. Tanner, C.M., Kamel, F., Ross, G.W., Hoppin, J.A., Goldman, S.M., Korell, M., Marras, C., Bhudhikanok, G.S., Kasten, M., Chade, A.R., *et al.* (2011) Rotenone, paraquat, and Parkinson's disease. *Environ. Health. Perspect.*, **119**, 866–872.
6. Pezzoli, G. and Cereda, E. (2013) Exposure to pesticides or solvents and risk of Parkinson disease. *Neurology*, **80**, 2035–2041.
7. Nandipati, S. and Litvan, I. (2016) Environmental exposures and Parkinson's disease. *Int. J. Environ. Res. Public. Health*, **13**.
8. Brooks, A.I., Chadwick, C.A., Gelbard, H.A., Cory-Slechta, D.A. and Federoff, H.J. (1999) Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. *Brain. Res.*, **823**, 1–10.
9. Ossowska, K., Wardas, J., Smiałowska, M., Kuter, K., Lenda, T., Wierońska, J.M., Zieba, B., Nowak, P., Dabrowska, J., Bortel, A., *et al.* (2005) A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats, an animal model of preclinical stages of Parkinson's disease ? *Eur. J. Neurosci.*, **22**, 1294–1304.
10. Peng, J., Stevenson, F.F., Doctrow, S.R. and Andersen, J.K. (2005) Superoxide dismutase/catalase mimetics are neuroprotective against selective paraquat-mediated dopaminergic neuron death in the substantia nigra, implications for Parkinson disease. *J. Biol. Chem.*, **280**, 29194–29198.
11. Fernagut, P.O., Hutson, C.B., Fleming, S.M., Tetreault, N.A., Salcedo, J., Masliah, E. and Chesselet, M.F. (2007) Behavioral and histopathological consequences of paraquat intoxication in mice, effects of alpha-synuclein over-expression. *Synapse*, **61**, 991–1001.
12. Franco, R., Li, S., Rodriguez-Rocha, H., Burns, M. and Panayiotidis, M.I. (2010) Molecular mechanisms of pesticide-induced neurotoxicity, relevance to Parkinson's disease. *Chem. Biol. Interact.*, **188**, 289–300.
13. Bus, J.S. and Gibson, J.E. (1984) Paraquat, model for oxidant-initiated toxicity. *Environ. Health. Perspect.*, **55**, 37–46.

14. McCormack, A.L., Thiruchelvam, M., Manning-Bog, A.B., Thiffault, C., Langston, J.W., Cory-Slechta, D.A. and Di Monte, D.A. (2002) Environmental risk factors and Parkinson's disease, selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. *Neurobiol. Dis.*, **10**, 119–127.
15. Ramachandiran, S., Hansen, J.M., Jones, D.P., Richardson, J.R. and Miller, G.W. (2007) Divergent mechanisms of paraquat, MPP<sup>+</sup>, and rotenone toxicity, oxidation of thioredoxin and caspase-3 activation. *Toxicol. Sci.*, **95**, 163–171.
16. Cochemé, H.M. and Murphy, M.P. (2008) Complex I is the major site of mitochondrial superoxide production by paraquat. *J. Biol. Chem.*, **283**, 1786–1798.
17. Cristóvão, A.C., Choi, D.-H., Baltazar, G., Beal, M.F. and Kim, Y.-S. (2009) The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. *Antioxid. Redox Signal.*, **11**, 2105–2118.
18. Hosamani, R. and Muralidhara (2013) Acute exposure of *Drosophila melanogaster* to paraquat causes oxidative stress and mitochondrial dysfunction. *Arch. Insect. Biochem. Physiol.*, **83**, 25–40.
19. Reczek, C.R., Birsoy, K., Kong, H., Martínez-Reyes, I., Wang, T., Gao, P., Sabatini, D.M. and Chandel, N.S. (2017) A CRISPR screen identifies a pathway required for paraquat-induced cell death. *Nat. Chem. Biol.*, **13**, 1274–1279.
20. Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., Fournier, A., Chow, B.K.C., Hashimoto, H., Galas, L., *et al.* (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors, 20 years after the discovery. *Pharmacol. Rev.*, **61**, 283–357.
21. Seaborn, T., Masmoudi-Kouli, O., Fournier, A., Vaudry, H. and Vaudry, D. (2011) Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis. *Curr. Pharm. Des.*, **17**, 204–214.
22. Reglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S.B., Del-Bel, E. and Raisman-Vozari, R. (2017) Novel tactics for neuroprotection in Parkinson's disease, role of antibiotics, polyphenols and neuropeptides. *Prog. Neurobiol.*, **155**, 120–148.
23. Wang, G., Pan, J., Tan, Y.-Y., Sun, X.-K., Zhang, Y.-F., Zhou, H.-Y., Ren, R.-J., Wang, X.-J. and Chen, S.-D. (2008) Neuroprotective effects of PACAP27 in mice model of Parkinson's disease involved in the modulation of K(ATP) subunits and D2 receptors in the striatum. *Neuropeptides*, **42**, 267–276.
24. Dejda, A., Seaborn, T., Bourgault, S., Touzani, O., Fournier, A., Vaudry, H. and Vaudry, D. (2011) PACAP and a novel stable analog protect rat brain from ischemia, insight into the mechanisms of action. *Peptides*, **32**, 1207–1216.
25. Watson, M.B., Nobuta, H., Abad, C., Lee, S.K., Bala, N., Zhu, C., Richter, F., Chesselet, M.-F. and Waschek, J.A. (2013) PACAP deficiency sensitizes nigrostriatal dopaminergic neurons to

paraquat-induced damage and modulates central and peripheral inflammatory activation in mice. *Neuroscience*, **240**, 277–286.

26. Han, P., Tang, Z., Yin, J., Maalouf, M., Beach, T.G., Reiman, E.M. and Shi, J. (2014) Pituitary adenylate cyclase-activating polypeptide protects against  $\beta$ -amyloid toxicity. *Neurobiol. Aging*, **35**, 2064–2071.

27. Lamine, A., Létourneau, M., Doan, N.D., Maucotel, J., Couvineau, A., Vaudry, H., Chatenet, D., Vaudry, D. and Fournier, A. (2016) Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced *in vivo* cardiovascular side effects in a Parkinson's disease model. *Neuropharmacology*, **108**, 440–450.

28. Peng, J., Stevenson, F.F., Oo, M.L. and Andersen, J.K. (2009) Iron-enhanced paraquat-mediated dopaminergic cell death due to increased oxidative stress as a consequence of microglial activation. *Free Radic. Biol. Med.*, **46**, 312–320.

29. Pandey, U.B. and Nichols, C.D. (2011) Human disease models in *Drosophila melanogaster* and the role of the fly in therapeutic drug discovery. *Pharmacol. Rev.*, **63**, 411–436.

30. Jaiswal, M., Sandoval, H., Zhang, K., Bayat, V. and Bellen, H.J. (2012) Probing mechanisms that underlie human neurodegenerative diseases in *Drosophila*. *Annu. Rev. Genet.*, **46**, 371–396.

31. Fernández-Hernández, I., Scheenaard, E., Pollarolo, G. and Gonzalez, C. (2016) The translational relevance of *Drosophila* in drug discovery. *EMBO. Rep.*, **17**, 471–472.

32. Perrimon, N., Bonini, N.M. and Dhillon, P. (2016) Fruit flies on the front line, the translational impact of *Drosophila*. *Dis. Model. Mech.*, **9**, 229–231.

33. Coulom, H. and Birman, S. (2004) Chronic exposure to rotenone models sporadic Parkinson's disease in *Drosophila melanogaster*. *J. Neurosci.*, **24**, 10993–10998.

34. Chaudhuri, A., Bowling, K., Funderburk, C., Lawal, H., Inamdar, A., Wang, Z. and O'Donnell, J.M. (2007) Interaction of genetic and environmental factors in a *Drosophila* parkinsonism model. *J. Neurosci.*, **27**, 2457–2467.

35. Bayersdorfer, F., Voigt, A., Schneuwly, S. and Botella, J.A. (2010) Dopamine-dependent neurodegeneration in *Drosophila* models of familial and sporadic Parkinson's disease. *Neurobiol. Dis.*, **40**, 113–119.

36. Islam, R., Yang, L., Sah, M., Kannan, K., Anamani, D., Vijayan, C., Kwok, J., Cantino, M.E., Beal, M.F. and Fridell, Y.-W.C. (2012) A neuroprotective role of the human uncoupling protein 2 (hUCP2) in a *Drosophila* Parkinson's disease model. *Neurobiol. Dis.*, **46**, 137–146.

37. Martin, C.A., Barajas, A., Lawless, G., Lawal, H.O., Assani, K., Lumintang, Y.P., Nunez, V. and Krantz, D.E. (2014) Synergistic effects on dopamine cell death in a *Drosophila* model of chronic toxin exposure. *Neurotoxicology*, **44**, 344–351.

38. Varga, S.J., Qi, C., Podolsky, E. and Lee, D. (2014) A new *Drosophila* model to study the interaction between genetic and environmental factors in Parkinson's disease. *Brain. Res.*, **1583**, 277–286.
39. Cassar, M., Issa, A.-R., Riemensperger, T., Petitgas, C., Rival, T., Coulom, H., Iché-Torres, M., Han, K.-A. and Birman, S. (2015) A dopamine receptor contributes to paraquat-induced neurotoxicity in *Drosophila*. *Hum. Mol. Genet.*, **24**, 197–212.
40. Shukla, A.K., Pragma, P., Chaouhan, H.S., Tiwari, A.K., Patel, D.K., Abdin, M.Z. and Chowdhuri, D.K. (2014) Heat shock protein-70 (Hsp-70) suppresses paraquat-induced neurodegeneration by inhibiting JNK and caspase-3 activation in *Drosophila* model of Parkinson's disease. *PLoS. ONE*, **9**, e98886.
41. Nässel, D.R. and Winther, A.M.E. (2010) *Drosophila* neuropeptides in regulation of physiology and behavior. *Prog. Neurobiol.*, **92**, 42–104.
42. Taghert, P.H. and Nitabach, M.N. (2012) Peptide neuromodulation in invertebrate model systems. *Neuron*, **76**, 82–97.
43. Feany, M.B. and Quinn, W.G. (1995) A neuropeptide gene defined by the *Drosophila* memory mutant amnesiac. *Science*, **268**, 869–873.
44. Hashimoto, H., Shintani, N. and Baba, A. (2002) Higher brain functions of PACAP and a homologous *Drosophila* memory gene amnesiac, insights from knockouts and mutants. *Biochem. Biophys. Res. Commun.*, **297**, 427–431.
45. Pirger, Z., Krajcs, N. and Kiss, T. (2016) Occurrence, distribution, and physiological function of pituitary adenylyl cyclase-activating polypeptide in invertebrate species. In *Pituitary Adenylate Cyclase Activating Polypeptide — PACAP*, current topics in neurotoxicity. Springer, Cham, pp. 19–31.
46. Kiss, T. and Pirger, Z. (2013) Multifunctional role of PACAP-like peptides in molluscs. *Protein. Pept. Lett.*, **20**, 628–635.
47. Zhong, Y. and Peña, L.A. (1995) A novel synaptic transmission mediated by a PACAP-like neuropeptide in *Drosophila*. *Neuron*, **14**, 527–536.
48. Bhattacharya, A., Lakhman, S.S. and Singh, S. (2004) Modulation of L-type calcium channels in *Drosophila* via a pituitary adenylyl cyclase-activating polypeptide (PACAP)-mediated pathway. *J. Biol. Chem.*, **279**, 37291–37297.
49. Hyun, S., Lee, Y., Hong, S.-T., Bang, S., Paik, D., Kang, J., Shin, J., Lee, J., Jeon, K., Hwang, S., *et al.* (2005) *Drosophila* GPCR Han is a receptor for the circadian clock neuropeptide PDF. *Neuron*, **48**, 267–278.
50. Lear, B.C., Merrill, C.E., Lin, J.-M., Schroeder, A., Zhang, L. and Allada, R. (2005) A G

protein-coupled receptor, groom-of-PDF, is required for PDF neuron action in circadian behavior. *Neuron*, **48**, 221–227.

51. Mertens, I., Vandingenen, A., Johnson, E.C., Shafer, O.T., Li, W., Trigg, J.S., De Loof, A., Schoofs, L. and Taghert, P.H. (2005) PDF receptor signaling in *Drosophila* contributes to both circadian and geotactic behaviors. *Neuron*, **48**, 213–219.

52. Mertens, I., Husson, S.J., Janssen, T., Lindemans, M. and Schoofs, L. (2007) PACAP and PDF signaling in the regulation of mammalian and insect circadian rhythms. *Peptides*, **28**, 1775–1783.

53. Golombek, D.A. and Rosenstein, R.E. (2010) Physiology of circadian entrainment. *Physiol. Rev.*, **90**, 1063–1102.

54. Fifel, K. (2017) Alterations of the circadian system in Parkinson's disease patients. *Mov. Disord.*, **32**, 682–692.

55. Hood, S. and Amir, S. (2017) Neurodegeneration and the circadian clock. *Front. Aging. Neurosci.*, **9**, 170.

56. Torres, G. and Horowitz, J.M. (1998) Activating properties of cocaine and cocaethylene in a behavioral preparation of *Drosophilamelanogaster*. *Synapse*, **29**, 148–161.

57. Yellman, C., Tao, H., He, B. and Hirsh, J. (1997) Conserved and sexually dimorphic behavioral responses to biogenic amines in decapitated *Drosophila*. *Proc. Natl. Acad. Sci. U.S.A.*, **94**, 4131–4136.

58. Robberecht, P., Gourlet, P., De Neef, P., Woussen-Colle, M.C., Vandermeers-Piret, M.C., Vandermeers, A. and Christophe, J. (1992) Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP (6-38) as a potent antagonist. *Eur. J. Biochem.*, **207**, 239–246.

59. Tang, H.L., Tang, H.M., Fung, M.C. and Hardwick, J.M. (2015) *In vivo* CaspaseTracker biosensor system for detecting anastasis and non-apoptotic caspase activity. *Sci. Rep.*, **5**, 9015.

60. Im, S.H. and Taghert, P.H. (2010) PDF receptor expression reveals direct interactions between circadian oscillators in *Drosophila*. *J. Comp. Neurol.*, **518**, 1925–1945.

61. Krupp, J.J., Billeter, J.-C., Wong, A., Choi, C., Nitabach, M.N. and Levine, J.D. (2013) Pigment-dispersing factor modulates pheromone production in clock cells that influence mating in *Drosophila*. *Neuron*, **79**, 54–68.

62. Emery, P., So, W.V., Kaneko, M., Hall, J.C. and Rosbash, M. (1998) CRY, a *Drosophila* clock and light-regulated cryptochrome, is a major contributor to circadian rhythm resetting and photosensitivity. *Cell*, **95**, 669–679.

63. Kaneko, M. and Hall, J.C. (2000) Neuroanatomy of cells expressing clock genes in



*Drosophila*, transgenic manipulation of the period and timeless genes to mark the perikarya of circadian pacemaker neurons and their projections. *J. Comp. Neurol.*, **422**, 66–94.

64. Hamasaka, Y. and Nässel, D.R. (2006) Mapping of serotonin, dopamine, and histamine in relation to different clock neurons in the brain of *Drosophila*. *J. Comp. Neurol.*, **494**, 314–330.

65. Shafer, O.T. and Taghert, P.H. (2009) RNA-interference knockdown of *Drosophila* pigment dispersing factor in neuronal subsets, the anatomical basis of a neuropeptide's circadian functions. *PLoS ONE*, **4**, e8298.

66. Renn, S.C., Park, J.H., Rosbash, M., Hall, J.C. and Taghert, P.H. (1999) A pdf neuropeptide gene mutation and ablation of PDF neurons each cause severe abnormalities of behavioral circadian rhythms in *Drosophila*. *Cell*, **99**, 791–802.

67. Huang, W., Lyman, R.F., Lyman, R.A., Carbone, M.A., Harbison, S.T., Magwire, M.M. and Mackay, T.F. (2016) Spontaneous mutations and the origin and maintenance of quantitative genetic variation. *Elife*, **5**.

68. Nitabach, M.N., Sheeba, V., Vera, D.A., Blau, J. and Holmes, T.C. (2005) Membrane electrical excitability is necessary for the free-running larval *Drosophila* circadian clock. *J. Neurobiol.*, **62**, 1–13.

69. Choi, C., Cao, G., Tanenhaus, A.K., McCarthy, E.V., Jung, M., Schleyer, W., Shang, Y., Rosbash, M., Yin, J.C.P. and Nitabach, M.N. (2012) Autoreceptor control of peptide/neurotransmitter corelease from PDF neurons determines allocation of circadian activity in *Drosophila*. *Cell. Rep.*, **2**, 332–344.

70. Beckwith, E.J. and Ceriani, M.F. (2015) Communication between circadian clusters, the key to a plastic network. *FEBS. Lett.*, **589**, 3336–3342.

71. Shafer, O.T., Kim, D.J., Dunbar-Yaffe, R., Nikolaev, V.O., Lohse, M.J. and Taghert, P.H. (2008) Widespread receptivity to neuropeptide PDF throughout the neuronal circadian clock network of *Drosophila* revealed by real-time cyclic AMP imaging. *Neuron*, **58**, 223–237.

72. Park, J.H., Helfrich-Förster, C., Lee, G., Liu, L., Rosbash, M. and Hall, J.C. (2000) Differential regulation of circadian pacemaker output by separate clock genes in *Drosophila*. *Proc. Natl. Acad. Sci. U.S.A.*, **97**, 3608–3613.

73. Friggi-Grelin, F., Coulom, H., Meller, M., Gomez, D., Hirsh, J. and Birman, S. (2003) Targeted gene expression in *Drosophila* dopaminergic cells using regulatory sequences from tyrosine hydroxylase. *J. Neurobiol.*, **54**, 618–627.

74. Feinberg, E.H., Vanhoven, M.K., Bendesky, A., Wang, G., Fetter, R.D., Shen, K. and Bargmann, C.I. (2008) GFP Reconstitution Across Synaptic Partners (GRASP) defines cell contacts and synapses in living nervous systems. *Neuron*, **57**, 353–363.

75. Macpherson, L.J., Zaharieva, E.E., Kearney, P.J., Alpert, M.H., Lin, T.-Y., Turan, Z., Lee, C.-

- H. and Gallio, M. (2015) Dynamic labelling of neural connections in multiple colours by trans-synaptic fluorescence complementation. *Nat. Commun.*, **6**, 10024.
76. Journot, L., Villalba, M. and Bockaert, J. (1998) PACAP-38 protects cerebellar granule cells from apoptosis. *Ann. N. Y. Acad. Sci.*, **865**, 100–110.
77. Masmoudi-Kouki, O., Douiri, S., Hamdi, Y., Kaddour, H., Bahdoudi, S., Vaudry, D., Basille, M., Leprince, J., Fournier, A., Vaudry, H., *et al.* (2011) Pituitary adenylate cyclase-activating polypeptide protects astroglial cells against oxidative stress-induced apoptosis. *J. Neurochem.*, **117**, 403–411.
78. Waschek, J.A. (2013) VIP and PACAP, neuropeptide modulators of CNS inflammation, injury, and repair. *Br. J. Pharmacol.*, **169**, 512–523.
79. Lee, E.H. and Seo, S.R. (2014) Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases. *BMB. Rep.*, **47**, 369–375.
80. Douiri, S., Bahdoudi, S., Hamdi, Y., Cubi, R., Basille, M., Fournier, A., Vaudry, H., Tonon, M.-C., Amri, M., Vaudry, D., *et al.* (2016) Involvement of endogenous antioxidant systems in the protective activity of pituitary adenylate cyclase-activating polypeptide against hydrogen peroxide-induced oxidative damages in cultured rat astrocytes. *J. Neurochem.*, **137**, 913–930.
81. Reglodi, D., Tamas, A., Jungling, A., Vaczy, A., Rivnyak, A., Fulop, B.D., Szabo, E., Lubics, A. and Atlasz, T. (2018) Protective effects of pituitary adenylate cyclase activating polypeptide against neurotoxic agents. *Neurotoxicology*, **66**, 185–194.
82. Maasz, G., Zrinyi, Z., Reglodi, D., Petrovics, D., Rivnyak, A., Kiss, T., Jungling, A., Tamas, A. and Pirger, Z. (2017) Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models. *Dis. Model. Mech.*, **10**, 127–139.
83. Heimesaat, M.M., Dunay, I.R., Schulze, S., Fischer, A., Grundmann, U., Alutis, M., Kühl, A.A., Tamas, A., Toth, G., Dunay, M.P., *et al.* (2014) Pituitary adenylate cyclase-activating polypeptide ameliorates experimental acute ileitis and extra-intestinal sequelae. *PLoS ONE*, **9**, e108389.
84. Szakaly, P., Kiss, P., Lubics, A., Magyarlaki, T., Tamas, A., Racz, B., Lengvari, I., Toth, G. and Reglodi, D. (2008) Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia/reperfusion. *J. Mol. Neurosci.*, **36**, 89–96.
85. Gray, S.L., Yamaguchi, N., Vencová, P. and Sherwood, N.M. (2002) Temperature-sensitive phenotype in mice lacking pituitary adenylate cyclase-activating polypeptide. *Endocrinology*, **143**, 3946–3954.
86. Mori, H., Nakamachi, T., Ohtaki, H., Yofu, S., Sato, A., Endo, K., Iso, Y., Suzuki, H., Takeyama, Y., Shintani, N., *et al.* (2010) Cardioprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on doxorubicin-induced cardiomyopathy in mice. *Circ.*

*J.*, **74**, 1183–1190.

87. Shukla, A.K., Ratnasekhar, C., Pragya, P., Chaouhan, H.S., Patel, D.K., Chowdhuri, D.K. and Mudiam, M.K.R. (2016) Metabolomic analysis provides insights on paraquat-induced Parkinson-like symptoms in *Drosophila melanogaster*. *Mol. Neurobiol.*, **53**, 254–269.

88. Miyamoto, K., Tsumuraya, T., Ohtaki, H., Dohi, K., Satoh, K., Xu, Z., Tanaka, S., Murai, N., Watanabe, J., Sugiyama, K., *et al.* (2014) PACAP38 suppresses cortical damage in mice with traumatic brain injury by enhancing antioxidant activity. *J. Mol. Neurosci.*, **54**, 370–379.

89. Mehdi, S.H. and Qamar, A. (2013) Paraquat-induced ultrastructural changes and DNA damage in the nervous system is mediated via oxidative-stress-induced cytotoxicity in *Drosophila melanogaster*. *Toxicol. Sci.*, **134**, 355–365.

90. Vaudry, D., Gonzalez, B.J., Basille, M., Pamantung, T.F., Fontaine, M., Fournier, A. and Vaudry, H. (2000) The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32. *Proc. Natl. Acad. Sci. U.S.A.*, **97**, 13390–13395.

91. Pirger, Z., Nemeth, J., Hiripi, L., Toth, G., Kiss, P., Lubics, A., Tamas, A., Hernadi, L., Kiss, T. and Reglodi, D. (2008) PACAP has anti-apoptotic effect in the salivary gland of an invertebrate species, *Helix pomatia*. *J. Mol. Neurosci.*, **36**, 105–114.

92. Peng, J., Mao, X.O., Stevenson, F.F., Hsu, M. and Andersen, J.K. (2004) The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway. *J. Biol. Chem.*, **279**, 32626–32632.

93. Fei, Q., McCormack, A.L., Di Monte, D.A. and Ethell, D.W. (2008) Paraquat neurotoxicity is mediated by a Bak-dependent mechanism. *J. Biol. Chem.*, **283**, 3357–3364.

94. Dejda, A., Jolivel, V., Bourgault, S., Seaborn, T., Fournier, A., Vaudry, H. and Vaudry, D. (2008) Inhibitory effect of PACAP on caspase activity in neuronal apoptosis, a better understanding towards therapeutic applications in neurodegenerative diseases. *J. Mol. Neurosci.*, **36**, 26–37.

95. Li, Y., Guo, F., Shen, J. and Rosbash, M. (2014) PDF and cAMP enhance PER stability in *Drosophila* clock neurons. *Proc. Natl. Acad. Sci. U.S.A.*, **111**, E1284–1290.

96. Seluzicki, A., Flourakis, M., Kula-Eversole, E., Zhang, L., Kilman, V. and Allada, R. (2014) Dual PDF signaling pathways reset clocks via TIMELESS and acutely excite target neurons to control circadian behavior. *PLoS. Biol.*, **12**, e1001810.

97. Vecsey, C.G., Pérez, N. and Griffith, L.C. (2014) The *Drosophila* neuropeptides PDF and snPF have opposing electrophysiological and molecular effects on central neurons. *J. Neurophysiol.*, **111**, 1033–1045.

98. Yao, Z. and Shafer, O.T. (2014) The *Drosophila* circadian clock is a variably coupled network

of multiple peptidergic units. *Science*, **343**, 1516–1520.

99. Choi, C., Fortin, J.-P., McCarthy, E. v, Oksman, L., Kopin, A.S. and Nitabach, M.N. (2009) Cellular dissection of circadian peptide signals with genetically encoded membrane-tethered ligands. *Curr. Biol.*, **19**, 1167–1175.
100. Agrawal, T., Sadaf, S. and Hasan, G. (2013) A genetic RNAi screen for IP<sub>3</sub>/Ca<sup>2+</sup> coupled GPCRs in *Drosophila* identifies the PdfR as a regulator of insect flight. *PLoS. Genet.*, **9**, e1003849.
101. Liang, X., Holy, T.E. and Taghert, P.H. (2017) A series of suppressive signals within the *Drosophila* circadian neural circuit generates sequential daily outputs. *Neuron*, **94**, 1173–1189
102. Means, J.C., Venkatesan, A., Gerdes, B., Fan, J.-Y., Bjes, E.S. and Price, J.L. (2015) *Drosophila* spaghetti and doubletime link the circadian clock and light to caspases, apoptosis and tauopathy. *PLoS. Genet.*, **11**.
103. Vaccaro, A., Issa, A.-R., Seugnet, L., Birman, S. and Klarsfeld, A. (2017) *Drosophila* clock is required in brain pacemaker neurons to prevent premature locomotor aging independently of its circadian function. *PLoS. Genet.*, **13**, e1006507.
104. Emery, P. (2015) Connecting circadian genes to neurodegenerative pathways in fruit flies. *PLoS. Genet.*, **11**, e1005266.
105. He, Q., Wu, B., Price, J.L. and Zhao, Z. (2017) Circadian rhythm neuropeptides in *Drosophila*, signals for normal circadian function and circadian neurodegenerative disease. *Int. J. Mol. Sci.*, **18**.
106. Giebultowicz, J.M. (2018) Circadian regulation of metabolism and healthspan in *Drosophila*. *Free Radic. Biol. Med.*, **119**, 62–68.
107. Helfrich-Förster, C. (1997) Development of pigment-dispersing hormone-immunoreactive neurons in the nervous system of *Drosophila melanogaster*. *J. Comp. Neurol.*, **380**, 335–354.
108. Santos, J.G., Vömel, M., Struck, R., Homberg, U., Nässel, D.R. and Wegener, C. (2007) Neuroarchitecture of peptidergic systems in the larval ventral ganglion of *Drosophila melanogaster*. *PLoS. ONE*, **2**, e695.
109. Potdar, S. and Sheeba, V. (2018) Wakefulness is promoted during day time by PDFR signalling to dopaminergic neurons in *Drosophila melanogaster*. *eNeuro*, **5**, 1-17.
110. Lin, D.M. and Goodman, C.S. (1994) Ectopic and increased expression of Fasciclin II alters motoneuron growth cone guidance. *Neuron*, **13**, 507–523.
111. Sepp, K.J., Schulte, J. and Auld, V.J. (2001) Peripheral glia direct axon guidance across the CNS/PNS transition zone. *Dev. Biol.*, **238**, 47–63.

112. Berry, J.A., Cervantes-Sandoval, I., Chakraborty, M. and Davis, R.L. (2015) Sleep facilitates memory by blocking dopamine neuron-mediated forgetting. *Cell*, **161**, 1656–1667.
113. Paradis, S., Sweeney, S.T. and Davis, G.W. (2001) Homeostatic control of presynaptic release is triggered by postsynaptic membrane depolarization. *Neuron*, **30**, 737–749.
114. Riemensperger, T., Issa, A.-R., Pech, U., Coulom, H., Nguyễn, M.-V., Cassar, M., Jacquet, M., Fiala, A. and Birman, S. (2013) A single dopamine pathway underlies progressive locomotor deficits in a *Drosophila* model of Parkinson disease. *Cell. Rep*, **5**, 952–960.
115. Jolivel, V., Basille, M., Aubert, N., de Jouffrey, S., Ancian, P., Le Bigot, J.-F., Noack, P., Massonneau, M., Fournier, A., Vaudry, H., *et al.* (2009) Distribution and functional characterization of pituitary adenylate cyclase-activating polypeptide receptors in the brain of non-human primates. *Neuroscience*, **160**, 434–451.
116. Evans, C.J., Olson, J.M., Ngo, K.T., Kim, E., Lee, N.E., Kuoy, E., Patananan, A.N., Sitz, D., Tran, P., Do, M.-T., *et al.* (2009) G-TRACE, rapid Gal4-based cell lineage analysis in *Drosophila*. *Nat. Methods*, **6**, 603–605.
117. Owusu-Ansah, E., Yavari, A. and Banerjee, U. (2008) A protocol for *in vivo* detection of reactive oxygen species. *Protocol. Exchange*, 10.1038/nprot.2008.23.
118. Issa, A.-R., Sun, J., Petitgas, C., Mesquita, A., Dulac, A., Robin, M., Mollereau, B., Jenny, A., Chérif-Zahar, B. and Birman, S. (2018) The lysosomal membrane protein LAMP2A promotes autophagic flux and prevents SNCA-induced Parkinson disease-like symptoms in the *Drosophila* brain. *Autophagy*, **14**, 1898–1910.
119. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., *et al.* (2012) Fiji, an open-source platform for biological-image analysis. *Nature. Methods*, **9**, 676–682.
120. Riemensperger, T., Isabel, G., Coulom, H., Neuser, K., Seugnet, L., Kume, K., Iché-Torres, M., Cassar, M., Strauss, R., Preat, T., *et al.* (2011) Behavioral consequences of dopamine deficiency in the *Drosophila* central nervous system. *Proc. Natl. Acad. Sci. U.S.A.*, **108**, 834–839.

## Figures Legend

**Figure 1.** PACAP decreases PQ-induced oxidative stress and caspase activation in the *Drosophila* CNS. (A) Application of 80 mM PQ to the VNC decreased fly survival compared to controls treated with Ringer's (R) solution only (R + PQ vs R + R,  $###p < 0.001$ ). Pretreatment with 2  $\mu$ M PACAP (P) during 30 min had no effect by itself (P + R vs R + R) but markedly delayed PQ-induced lethality. The protective action of PACAP was significant until 3 hours after PQ application (P + PQ vs R + PQ,  $**p < 0.01$ ,  $***p < 0.001$ ). Two-way ANOVA with Tukey's *post-hoc* test. (B, C) Evaluation of ROS levels in the VNC after 90 min of PQ exposure. (B) Flies pretreated with 2  $\mu$ M PACAP (*right panel*) showed reduced DHE fluorescent staining indicating lower ROS in the VNC than flies exposed to PQ only (*left panel*). Scale bar: 50  $\mu$ m. (C) Quantification of the effect of PACAP on PQ-induced ROS accumulation in the VNC. Student's t test,  $**p < 0.01$ . (D, E) Effect of PACAP on caspase activation induced by PQ exposure after 90 min, as detected by the CaspaseTracker biosensor system. (D) Pre-application of 2  $\mu$ M PACAP significantly decreased the number of activated caspase-positive VNC cells in decapitated flies treated with PQ (*right panel*) compared to flies exposed to PQ only (*left panel*). Scale bar: 50  $\mu$ m. (E) Quantification of the effect of PACAP on PQ-induced caspase activation in VNC cells. Student's t test,  $**p < 0.01$ .

**Figure 2.** *Pdfr* knock down in all neurons or all clock cells increases PQ resistance. (A) Survival kinetics of PQ-intoxicated *elav>Pdfr<sup>RNAi</sup>*, *Dcr-2* flies compared to *elav>Dcr-2* controls, pre-treated (P + PQ) or not (R + PQ) with PACAP. *Pdfr* downregulation in all neurons strongly mitigated PQ-induced lethality (as also shown in Table 1) and the survival of these flies was not further increased by PACAP, in contrast to the *elav>Dcr-2* control flies. (B) Overexpression of *Pdfr* in all

neurons (*elav>Pdf*) did not alter *Drosophila* PQ susceptibility, as compared to the heterozygous driver (*elav/+*) and effector (*Pdf/+*) controls. (C) *Pdf* downregulation in all clock cells with the *tim-Gal4* driver (*tim>Pdf<sup>RNAi</sup>*, *Dcr-2*) significantly protected flies against PQ compared to the survival rate of *Pdf<sup>RNAi/+</sup>*; *Dcr-2/+* controls (R + PQ). No further protection could be observed by PACAP pre-application on the *tim>Pdf<sup>RNAi</sup>*, *Dcr-2* flies, whereas the *Pdf<sup>RNAi/+</sup>*; *Dcr-2/+* controls were strongly protected by PACAP (P + PQ). (D) Monitoring the survival of PQ-treated *elav>Pdf<sup>RNAi</sup>*, *Dcr-2* and *tim>Pdf<sup>RNAi</sup>*, *Dcr-2* flies in a parallel experiment showed similar levels of protection compared to *Pdf<sup>RNAi/+</sup>*; *Dcr-2/+* controls when *Pdf* was down-regulated in neurons (\*) or in clock cells (#). Two-way ANOVA with Tukey's *post-hoc* test: \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001, ##*p* < 0.001, ###*p* < 0.001, ns: not significant.

**Figure 3.** Lack of PACAP-induced neuroprotection in *Pdf* and *Pdf* null mutants. (A) In the absence of PDF receptor (mutant *Pdf<sup>5304</sup>*), PQ resistance was not significantly different(ns) from that of wild-type CS flies (*Pdf<sup>5304</sup>*, R + PQ vs CS, R + PQ), and no protective effect of PACAP against PQ could be observed in these mutant flies (*Pdf<sup>5304</sup>*, P + PQ vs R + PQ). (B) Without expressed PDF neuropeptide (mutant *Pdf<sup>01</sup>*), flies were also not more resistant to PQ than wild type, and again PACAP did not protect against PQ (ns). (C) The hyperpolarization of PDF-releasing neurons (*Pdf>Kir2.1* flies) had no effect in normal conditions (Ringer, R) but increased PQ resistance at 60 and 90 min of exposure compared to driver (PDF/+) and effector (*Kir2.1/+*) controls. (D) Direct pre-application of 2  $\mu$ M PDF neuropeptide on the VNC of decapitated flies did not affect their survival rate under control (PDF + R versus R + R) or PQ-intoxicated (PDF + PQ versus R + PQ) conditions (ns). Two-way ANOVA with Tukey's *post-hoc* test: \**p* < 0.05, \*\*\**p* < 0.001, ns: not significant.

**Figure 4.** Selective *Pdfr* knock down in PDF or DA neurons prevents PACAP-mediated neuroprotection. (A) *Pdfr* downregulation targeted to PDF neurons with the *Pdf-Gal4* driver did not protect against PQ but efficiently suppressed PACAP-induced increase in PQ resistance, i.e. the survival of *Pdf>Pdfr<sup>RNAi</sup>, Dcr-2* flies was not different in P + PQ and R + PQ conditions. The control flies (*Pdf-Gal4/+*) were in contrast normally protected by a PACAP pre-treatment (P + PQ vs R + PQ: \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ). (B) *Pdfr* knock down selectively in the Abd PDF neurons using *Dot-Gal4* also suppressed the protective effect of PACAP and did not increase PQ resistance. The survival of *Dot>Pdfr<sup>RNAi</sup>, Dcr-2* flies was similar in P+PQ and R+PQ conditions, whereas PACAP pre-treatment fully protected the control flies (*Dot-Gal4/+*) from PQ toxicity (P+PQ vs R+PQ: \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ). (C) PDFR downregulation in DA neurons with *TH-Gal4* (*TH>Pdfr<sup>RNAi</sup>, Dcr-2*) similarly prevented PACAP-induced neuroprotection compared to controls (i.e. survival of *TH>Pdfr<sup>RNAi</sup>, Dcr-2* flies was not significantly different in P + PQ and R + PQ conditions at all times) and also did not change PQ susceptibility, whereas the effector control flies (*Pdfr<sup>RNAi</sup>/+; Dcr-2/+*) were well protected by PACAP pre-treatment (P + PQ vs R + PQ: \* $p < 0.05$ , \*\* $p < 0.01$ ). Two-way ANOVA with Tukey's *post-hoc* test.

**Figure 5.** Identification of potential synaptic connections between PDF and DA neurons in the *Drosophila* VNC by split-GFP reconstitution. The fusion protein n-Syb::spGFP<sub>1-10</sub>, which is targeted to synaptic terminals, was expressed in PDF neurons with *Pdf-Gal4* (*PDF>nSyb::GFP<sub>1-10</sub>*) and the fusion membrane protein CD4::spGFP<sub>11</sub> was expressed in DA neurons with *TH-LexA* (*TH>CD4::spGFP<sub>11</sub>*). TH (magenta) and GFP (green) co-immunostaining. (A) TH immunostaining. (B) GFP immunostaining. (C) Merge. Reconstituted split GFP (rsGFP) fluorescence specifically labelled bilateral axon bundles of DA neurons localized in the abdominal ganglia of the VNC (arrowheads in B and C). Scale bar: 100  $\mu$ m.



**Table 1.** Effect of neuropeptide receptor downregulation on *Drosophila* PQ susceptibility

Fly genotype	<i>elav&gt;Dcr-2</i>		<i>elav&gt;R<sup>RNAi</sup>, Dcr-2</i>	
	PQ	PACAP + PQ	PQ	PACAP + PQ
<i>DH31-R</i>	45	85***	49	84***
<i>DH44-R1</i>	54	76**	46	62,5*
<i>DH44-R2</i>	34	71***	45	72**
<i>sNPF-R</i>	46	75***	38	71***
<i>FMRFaR</i>	41	65**	39	59*
<i>Pdfr</i>	45	90***	77 <sup>###</sup>	82

Genes encoding various neuropeptide GPCRs were knocked down by co-expressing specific interfering double-stranded RNAs (*R<sup>RNAi</sup>*) and the RNAi booster *Dcr-2* in all neurons with the driver *elav-Gal4*(*elav>R<sup>RNAi</sup>, Dcr-2*flies) or *Dcr-2* only for controls (*elav>Dcr-2*flies). The numbers indicate the percent of surviving flies 90 min after application of PQ without (PQ) or with (PACAP + PQ) pre-treatment with 2  $\mu$ M PACAP. Statistical significance: PACAP + PQ vs PQ, \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ; PQ (*elav>R<sup>RNAi</sup>, Dcr-2*)vsPQ (*elav>Dcr-2*), <sup>###</sup> $p < 0.001$ . One-way ANOVA with Tukey's post-hoc multiple comparison test.

## **Abbreviations used**

Clk, Clock; CNS, central nervous system; CS, Canton-S; DA, dopamine; DA neurons, dopaminergic neurons; DHE, dihydroethidium; GFP: green fluorescent protein; GPCR, G protein-coupled receptor; GPX1, glutathione peroxidase 1; GRASP, GFP reconstitution across synaptic partners; GSH, glutathione; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; ns: not significant; PACAP, pituitary adenylate cyclase-activating polypeptide; PBS, phosphate-buffered saline; PD, Parkinson's disease; PDF, Pigment dispersing factor; PDFR, PDF receptor; PKA, protein kinase A; PQ, paraquat/1,1'-dimethyl-4-4'-bipyridinium; RFP, red fluorescent protein; RNAi, RNA interference; ROS, reactive oxygen species; rsGFP: reconstituted split GFP; SNpc, substantia nigra pars compacta; SOD, superoxide dismutase; TH, tyrosine hydroxylase; VIP, vasoactive intestinal peptide; VNC, ventral nerve cord; vs: versus.

## Supplementary figure legends

**Figure S1.** PACAP protects *Drosophila* against DA neurotoxicity. Application of 35 mM DA to the exposed VNC of decapitated flies significantly decreased fly survival compared to controls (R + DA vs R + R, # $p < 0.05$ , ## $p < 0.01$ ). A 30-min pretreatment with 2  $\mu$ M PACAP prevented DA-induced fly death (P + DA vs R + DA, \* $p < 0.05$ , \*\*\* $p < 0.001$ ). Two-way ANOVA with Tukey's *post-hoc* test. (Related to Figure 1).

**Figure S2.** The PACAP receptor antagonist PACAP-6-38 increases *Drosophila* susceptibility to PQ. Pre-treatment with 2  $\mu$ M PACAP-6-38 (P-6-38) for 30 min significantly accelerated the death of decapitated flies intoxicated by PQ (P-6-38 + PQ vs R + PQ, \*\*\* $p < 0.001$ ), compared to control flies pre-treated with Ringer's only (R + PQ vs R + R, ### $p < 0.001$ ), indicating that the antagonist makes *Drosophila* more sensitive to oxidative stress. PACAP-6-38 had no effect by itself on fly survival in the absence of PQ (P-6-38+R vs R+ R). Two-way ANOVA with Tukey's *post-hoc* test. (Related to Figure 1).


**Figure S3.** *Pdfr* downregulation in glial cells does not increase fly PQ resistance. The survival rate of PQ-treated *repo>Pdfr<sup>RNAi</sup>*; *Dcr-2* decapitated flies was not improved compared to *Pdfr<sup>RNAi</sup>/+*; *Dcr-2/+* controls (ns: not significant). (Related to Figure 2).

**Figure S4.** Expression pattern of the *tim-Gal4* driver in the abdominal ganglia. (A, B) Whole-mount GFP and PDF co-immunostaining in the VNC of young adult *Drosophila* expressing membrane-associated GFP under *tim-Gal4* control (*tim>mCD8::GFP*, *nSyb::GFP* flies). (A) *tim-*


*Gal4* expresses in neuronal subsets in the abdominal ganglia and in characteristic bilateral axonal bundles (arrows) that may project from dopaminergic cell bodies (see Fig. 5). **(B)** PDF co-immunostaining shows that *tim-Gal4* does not express in the Abd PDF neurons. Scale bar: 50  $\mu$ m. (Related to Figure 2 and 5).

**Figure S5.** No effect of PDF on PQ susceptibility of wild-type flies. Direct application of 20  $\mu$ M PDF to the VNC of decapitated flies did not alter their survival rate under normal (PDF + R versus R + R) or PQ-intoxicated (PDF + PQ versus R + PQ) conditions (ns: not significant). (Related to Figure 3).


**A**




**B**




**C**




**D**




**E**




**A**




**B**







**C**






**D**




Hajji et al. Figure 2

**A****B****C****D**Hajji *et al.* Figure 3


**A****B****C**






*Pdf>nSyb::GFP<sub>1-10</sub> + TH>CD4::spGFP<sub>11</sub>*


Hajji *et al.* Figure 5




Hajji *et al.* Figure S1




Hajji *et al.* Figure S2





Hajji *et al.* Figure S4



Hajji *et al.* Figure S5